<DOC>
	<DOCNO>NCT02695121</DOCNO>
	<brief_summary>The primary objective study ( 1 ) compare incidence breast cancer , insulin use cohort entry , among female type 2 diabetes new user dapagliflozin females new user antidiabetic drug ( ADs ) class sodium-glucose cotransporter 2 ( SGLT2 ) inhibitor , insulin monotherapy , metformin monotherapy , sulfonylurea monotherapy ( 2 ) compare incidence bladder cancer , insulin use cohort entry pioglitazone use , among male female patient type 2 diabetes new user dapagliflozin new user ADs class SGLT2 inhibitor , insulin monotherapy , metformin monotherapy , sulfonylurea monotherapy . Secondary objective compare , insulin use cohort entry , frequency several measure health care use , baseline characteristic , incidence select cancer male female two exposure cohort .</brief_summary>
	<brief_title>Cancer Patients Dapagliflozin Other Antidiabetic Treatment</brief_title>
	<detailed_description>This multinational cohort database study estimate incidence female breast cancer bladder cancer , insulin use cohort entry , patient prescribe dapagliflozin compare patient prescribe specific oral antidiabetic drug . Dapagliflozin antidiabetic drug use treat type 2 diabetes mellitus . Because mechanism action dapagliflozin result small safety monitoring study , interest evaluate safety dapagliflozin large population . The study implement four administrative health care data source three country : United Kingdom , Clinical Practice Research Datalink ( CPRD ) ; United States , Centers Medicare Medicaid Services ( CMS ) Medicare databases HealthCore Integrated Research Database ( HIRDSM ) ; , Netherlands , PHARMO Database Network . Individuals database include study meet follow age criterion ; 40 year old ( CPRD PHARMO ) , 40 64 year ( HIRD ) 65 year old ( Medicare ) ; type 1 diabetes , treat one study drug meet criterion least 180 day electronic data first prescription study drug . The study period start November 13 , 2012 CPRD , November 1 , 2013 PHARMO January 9 , 2014 United States data source , end late available data database time analysis .</detailed_description>
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<mesh_term>Hypoglycemic Agents</mesh_term>
	<criteria>1. patient newly prescribe dapagliflozin newly prescribe AD ( without ADs ) class SGLT2 inhibitor , insulin monotherapy , metformin monotherapy , sulfonylurea monotherapy prescription index date 2. patient age 40 year old cohort entry ; 3. patient enrol data source least 180 day prescription index date . 1. evidence diagnosis type 1 diabetes cohort entry use insulin alone first recorded AD ; 2. diagnosis cancer cohort entry ( nonmelanoma skin cancer ) ; 3. record hematuria cohort entry ; 4. cystoscopy urine cytology perform cohort entry ; 5. breast biopsy perform cohort entry .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>